AbbVie (NYSE:ABBV) Price Target Raised to $220.00

AbbVie (NYSE:ABBV) had its price target raised by equities research analysts at UBS Group from $195.00 to $220.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “neutral” rating on the stock. UBS Group’s target price indicates a potential upside of 0.53% from the company’s current price.

ABBV has been the subject of a number of other research reports. Evercore ISI boosted their price objective on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research report on Monday, September 22nd. Piper Sandler reaffirmed an “overweight” rating and set a $289.00 target price (up from $284.00) on shares of AbbVie in a report on Wednesday. JPMorgan Chase & Co. increased their price target on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday. HSBC set a $225.00 price target on AbbVie in a report on Thursday, October 2nd. Finally, Wells Fargo & Company upped their price objective on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $236.57.

AbbVie Stock Performance

Shares of ABBV traded down $0.20 during mid-day trading on Friday, hitting $218.84. The stock had a trading volume of 2,293,912 shares, compared to its average volume of 6,390,580. AbbVie has a fifty-two week low of $163.81 and a fifty-two week high of $244.81. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The company has a market cap of $386.60 billion, a PE ratio of 104.33, a PEG ratio of 1.42 and a beta of 0.50. The company’s fifty day simple moving average is $223.06 and its two-hundred day simple moving average is $201.96.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business’s revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts expect that AbbVie will post 12.31 earnings per share for the current year.

Insider Activity at AbbVie

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the sale, the executive vice president directly owned 177,292 shares in the company, valued at $35,178,278.64. The trade was a 19.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.25% of the stock is owned by insiders.

Institutional Investors Weigh In On AbbVie

Several hedge funds have recently modified their holdings of the stock. Brighton Jones LLC boosted its position in shares of AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares during the period. Revolve Wealth Partners LLC grew its stake in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new position in AbbVie in the first quarter worth approximately $59,000. Phillips Financial Management LLC increased its stake in shares of AbbVie by 4.1% during the 1st quarter. Phillips Financial Management LLC now owns 2,952 shares of the company’s stock worth $619,000 after purchasing an additional 117 shares during the last quarter. Finally, Cerity Partners LLC lifted its position in shares of AbbVie by 12.0% in the first quarter. Cerity Partners LLC now owns 979,028 shares of the company’s stock worth $205,126,000 after buying an additional 105,110 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.